Figure 5
From: Impaired placental neovascularization in mice with pregnancy-associated hypertension
Suppression of tissue-remodeling activities in the uteroplacental site of PAH placenta. (a) FIZ at E19 placenta. Uteroplacental sites are encircled by dotted lines. In WT placenta, strong proteolysis is demonstrated in the area coincided with uteroplacental site. On the other hand, in PAH placenta, no significant proteolysis is detected. (b) RT-PCR analysis of the uteroplacental site of the placenta in each period. MMP-2 mRNA at E16 in PAH is scarcely detected (dotted rectangle). Representative results obtained from three independent samples of each gestational day are presented. (c) Quantitative RT-PCR analysis of the uteroplacental site of the placenta. Marked downregulation of MMP-2 mRNA at E16 (dotted rectangle) and upregulation of TIMP-2 mRNA at E19 in PAH are demonstrated. **P<0.01, *P<0.05. (d) Gelatin zymography analysis in uteroplacental site at E19. The expression of pro-enzymatic form of MMP-2 (72 kDa) and active form of MMP-2 (arrow) is stronger in WT than in PAH. (e) Immunohistochemical stainings of Sca-1 in uteroplacental sites (upper) and labyrinths (lower) at E19. Intensive stainings for Sca-1 are detected in decidua basalis of WT whereas the stainings are weak and sparse in PAH.
